Literature DB >> 28214932

Theoretical and experimental study of polycyclic aromatic compounds as β-tubulin inhibitors.

Fabian E Olazarán1, Carlos A García-Pérez2, Debasish Bandyopadhyay3, Isaias Balderas-Rentería1, Angel D Reyes-Figueroa4, Lars Henschke5, Gildardo Rivera6.   

Abstract

In this work, through a docking analysis of compounds from the ZINC chemical library on human β-tubulin using high performance computer cluster, we report new polycyclic aromatic compounds that bind with high energy on the colchicine binding site of β-tubulin, suggesting three new key amino acids. However, molecular dynamic analysis showed low stability in the interaction between ligand and receptor. Results were confirmed experimentally in in vitro and in vivo models that suggest that molecular dynamics simulation is the best option to find new potential β-tubulin inhibitors. Graphical abstract Bennett's acceptance ratio (BAR) method.

Entities:  

Keywords:  Anticancer; Colchicine; Inhibitors; Virtual screening; β-Tubulin

Mesh:

Substances:

Year:  2017        PMID: 28214932     DOI: 10.1007/s00894-017-3256-5

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  35 in total

1.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.

Authors:  Raimond B G Ravelli; Benoît Gigant; Patrick A Curmi; Isabelle Jourdain; Sylvie Lachkar; André Sobel; Marcel Knossow
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

2.  ZINC--a free database of commercially available compounds for virtual screening.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

3.  Toward the identification of a reliable 3D QSAR pharmacophore model for the CCK2 receptor antagonism.

Authors:  Amit K Gupta; Kanika Varshney; Anil K Saxena
Journal:  J Chem Inf Model       Date:  2012-05-04       Impact factor: 4.956

4.  Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.

Authors:  Niamh M O'Boyle; Miriam Carr; Lisa M Greene; Orla Bergin; Seema M Nathwani; Thomas McCabe; David G Lloyd; Daniela M Zisterer; Mary J Meegan
Journal:  J Med Chem       Date:  2010-11-16       Impact factor: 7.446

5.  Biochemical characterization and molecular dynamic simulation of β-sitosterol as a tubulin-binding anticancer agent.

Authors:  Tejashree Mahaddalkar; Charu Suri; Pradeep Kumar Naik; Manu Lopus
Journal:  Eur J Pharmacol       Date:  2015-04-23       Impact factor: 4.432

6.  Vascular disrupting agents.

Authors:  John W Lippert
Journal:  Bioorg Med Chem       Date:  2006-10-27       Impact factor: 3.641

7.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

8.  Bioavailable pyrrolo-benzo-1,4-diazines as Na(v)1.7 sodium channel blockers for the treatment of pain.

Authors:  Shu-Wei Yang; Ginny D Ho; Deen Tulshian; Ana Bercovici; Zheng Tan; Jennifer Hanisak; Stephanie Brumfield; Julius Matasi; Xianfeng Sun; Samuel A Sakwa; R Jason Herr; Xiaoping Zhou; Terry Bridal; Mark Urban; Jeffrey Vivian; Diane Rindgen; Steve Sorota
Journal:  Bioorg Med Chem Lett       Date:  2014-09-19       Impact factor: 2.823

9.  In-silico Investigation of Tubulin Binding Modes of a Series of Novel Antiproliferative Spiroisoxazoline Compounds Using Docking Studies.

Authors:  Hoda Abolhasani; Afshin Zarghi; Maryam Hamzeh-Mivehroud; Ali Akbar Alizadeh; Javid Shahbazi Mojarrad; Siavoush Dastmalchi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

10.  Avogadro: an advanced semantic chemical editor, visualization, and analysis platform.

Authors:  Marcus D Hanwell; Donald E Curtis; David C Lonie; Tim Vandermeersch; Eva Zurek; Geoffrey R Hutchison
Journal:  J Cheminform       Date:  2012-08-13       Impact factor: 5.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.